Through a directed new share issue Medvasc receives SEK 3M with the purpose of conducting the first clinical study. in conjunction with the financing round Mats Nilsson from MAQS takes the position as Chairman and the entrepreneur Magnus Olsson also becomes a member of the Board.
Read more here
